KLP Kapitalforvaltning AS Has $549,000 Stake in LivaNova PLC $LIVN

KLP Kapitalforvaltning AS lifted its position in shares of LivaNova PLC (NASDAQ:LIVN) by 10.9% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,200 shares of the company’s stock after purchasing an additional 1,200 shares during the quarter. KLP Kapitalforvaltning AS’s holdings in LivaNova were worth $549,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Chapin Davis Inc. raised its position in shares of LivaNova by 15.3% during the second quarter. Chapin Davis Inc. now owns 19,600 shares of the company’s stock worth $882,000 after purchasing an additional 2,600 shares during the period. GAMMA Investing LLC grew its holdings in LivaNova by 182.5% during the second quarter. GAMMA Investing LLC now owns 630 shares of the company’s stock worth $28,000 after buying an additional 407 shares in the last quarter. Wealth Enhancement Advisory Services LLC bought a new stake in LivaNova during the second quarter worth $420,000. Harbor Capital Advisors Inc. grew its holdings in LivaNova by 20.3% during the second quarter. Harbor Capital Advisors Inc. now owns 102,165 shares of the company’s stock worth $4,599,000 after buying an additional 17,252 shares in the last quarter. Finally, Parallel Advisors LLC grew its holdings in LivaNova by 1,312.3% during the second quarter. Parallel Advisors LLC now owns 1,031 shares of the company’s stock worth $46,000 after buying an additional 958 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Stock Down 0.3%

Shares of NASDAQ:LIVN opened at $53.73 on Friday. The company has a market capitalization of $2.93 billion, a PE ratio of -13.81 and a beta of 0.95. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 1.09. The business has a fifty day moving average price of $54.30 and a two-hundred day moving average price of $46.37. LivaNova PLC has a 1 year low of $32.48 and a 1 year high of $58.91.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $1.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.84 by $0.21. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The firm had revenue of $352.50 million during the quarter, compared to the consensus estimate of $332.20 million. During the same quarter in the prior year, the company earned $0.93 EPS. The business’s revenue for the quarter was up 10.6% on a year-over-year basis. Analysts forecast that LivaNova PLC will post 2.85 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of LivaNova in a report on Wednesday, October 8th. Wall Street Zen upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 9th. The Goldman Sachs Group set a $55.00 price target on LivaNova and gave the stock a “neutral” rating in a report on Wednesday, October 1st. Needham & Company LLC reiterated a “buy” rating and set a $64.00 price target on shares of LivaNova in a report on Wednesday, September 3rd. Finally, Barclays upped their price target on LivaNova from $55.00 to $58.00 and gave the stock an “equal weight” rating in a report on Thursday, August 21st. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $59.71.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.